Provided by Tiger Trade Technology Pte. Ltd.

Cogent Biosciences, Inc.

36.73
+1.424.02%
Post-market: 36.33-0.4015-1.09%19:30 EDT
Volume:2.52M
Turnover:92.18M
Market Cap:6.37B
PE:-17.00
High:37.22
Open:35.75
Low:35.40
Close:35.31
52wk High:43.73
52wk Low:11.60
Shares:173.52M
Float Shares:166.83M
Volume Ratio:1.75
T/O Rate:1.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1600
EPS(LYR):-2.5504
ROE:-109.74%
ROA:-43.84%
PB:13.63
PE(LYR):-14.40

Loading ...

Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients With Nonadvanced Systemic Mastocytosis (Nonadvsm)

THOMSON REUTERS
·
Mar 16

U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics

Reuters
·
Mar 16

Cogent Biosciences Inc : Jefferies Assumes Coverage With Buy Rating; Price Target $55 VS $48

THOMSON REUTERS
·
Mar 16

J.P. Morgan Sticks to Its Buy Rating for Cogent Biosciences (COGT)

TIPRANKS
·
Mar 14

Cogent Biosciences (COGT) Valuation Check After New SUMMIT Trial Results For Bezuclastinib

Simply Wall St.
·
Mar 10

Cogent Biosciences (COGT) Receives a Buy from Stifel Nicolaus

TIPRANKS
·
Mar 03

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT), Aquestive Therapeutics (AQST) and Merck & Company (MRK)

TIPRANKS
·
Mar 02

Piper Sandler Keeps Their Buy Rating on Cogent Biosciences (COGT)

TIPRANKS
·
Mar 02

Cogent announces additional results from SUMMIT trial of bezuclastinib

TIPRANKS
·
Mar 02

Cogent Biosciences presents new 48-week SUMMIT trial data for bezuclastinib in NonAdvSM at AAAAI 2026

Reuters
·
Feb 28

Cogent Biosciences Grants Inducement Equity Awards to Three New Employees

Reuters
·
Feb 28

LifeSci Capital Remains a Buy on Cogent Biosciences (COGT)

TIPRANKS
·
Feb 21

H.C. Wainwright Sticks to Their Buy Rating for Cogent Biosciences (COGT)

TIPRANKS
·
Feb 20

Jefferies Sticks to Its Buy Rating for Cogent Biosciences (COGT)

TIPRANKS
·
Feb 18

Stock Track | Cogent Biosciences Soars 5.42% Intraday on Positive Analyst Ratings

Stock Track
·
Feb 18

Wedbush Remains a Buy on Cogent Biosciences (COGT)

TIPRANKS
·
Feb 18

Analysts Conflicted on These Healthcare Names: Danaher (DHR), Cogent Biosciences (COGT) and Masimo (MASI)

TIPRANKS
·
Feb 18